journal article·2016-01-02Open access

Recent advancements in the cardiovascular drug carriers

Baljeet Singh, Tarun Garg, Amit K. Goyal, Goutam Rath

Abstract

Cardiovascular disease is the disease that affects the cardiovascular system, vascular diseases of the brain and kidney, and peripheral arterial disease. Despite of all advances in pharmacological and clinical treatment, heart failure is a leading cause of morbidness and mortality worldwide. Many new therapeutic advance strategies, including cell transplantation, gene delivery or therapy, and cytokines or other small molecules, have been research to treat heart failure. The main aim of this review article is to focus on nano carriers advancement and addressing the problems associated with old and modern therapeutics such as nonspecific effects and poor stability.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Graphene and Nanomaterials Applications · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India

References (72)

Show source-provided references
1. Alwan A. · 2011
2. Anthea M · 1993 · 76
3. Arora N · Int Res J Pharm · 2012 · 3 · 102
4. Arora N · Int J Univ Pharm Life Sci · 2012 · 2 · 216
5. 10.1201/b11401-710.1201/b11401-7 ↗
6. 10.3109/10731199.2012.66240810.3109/10731199.2012.662408 ↗
7. 10.1016/j.ejpb.2008.09.02510.1016/j.ejpb.2008.09.025 ↗
8. 10.3389/fphys.2012.0032510.3389/fphys.2012.00325 ↗
9. 10.1124/mi.6.2.710.1124/mi.6.2.7 ↗
10. 10.1126/science.284.5417.114310.1126/science.284.5417.1143 ↗
11. Fuster V, Kelly BB. 2010 Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health Washington, DC: National Academies Press.
12. 10.1016/j.ejps.2013.11.01610.1016/j.ejps.2013.11.016 ↗
13. Garg T. · Int J Pharm Pharm Sci · 2012 · 4 · 590
14. Garg T. · Artif Cells Nanomed Biotechnol · 2014 · 1
15. Garg T · Int Res J Pharm · 2011 · 2 · 37
16. Garg T · Indo-global Res J Pharm Sci · 2012 · 2 · 182
17. Garg T · IOSR J Pharm · 2012 · 2 · 33810.9790/3021-0202338342 ↗
18. 10.2174/2210304x1120204000510.2174/2210304x11202040005 ↗
19. 10.1517/17425247.2014.89101410.1517/17425247.2014.891014 ↗
20. 10.2174/2210303111303666001510.2174/22103031113036660015 ↗
21. 10.2174/2210304x1120204000310.2174/2210304x11202040003 ↗
22. Garg T · 2014
23. Garg T · Int J Pharm Sci Rev Res · 2011 · 7 · 211
24. 10.1615/CritRevTherDrugCarrierSyst.v29.i1.1010.1615/CritRevTherDrugCarrierSyst.v29.i1.10 ↗
25. 10.1615/CritRevTherDrugCarrierSyst.201300725910.1615/CritRevTherDrugCarrierSyst.2013007259 ↗
26. 10.1289/ehp.800610.1289/ehp.8006 ↗
27. 10.1007/978-3-662-45775-7_410.1007/978-3-662-45775-7_4 ↗
28. Goyal G · 2013
29. Gundogdu E · 2014
30. 10.1016/j.ijpharm.2011.04.05510.1016/j.ijpharm.2011.04.055 ↗
31. Huang CC · Adv Healthc Mater · 2014
32. 10.1007/s10047-011-0595-310.1007/s10047-011-0595-3 ↗
33. 10.5731/pdajpst.2013.0091610.5731/pdajpst.2013.00916 ↗
34. 10.1016/j.addr.2010.08.00410.1016/j.addr.2010.08.004 ↗
35. 10.1021/nl104329y10.1021/nl104329y ↗
36. 10.1016/j.jvs.2007.02.04810.1016/j.jvs.2007.02.048 ↗
37. 10.1007/BF0321869010.1007/BF03218690 ↗
38. 10.1016/j.ejpb.2005.12.01310.1016/j.ejpb.2005.12.013 ↗
39. 10.2174/2210303111303666001810.2174/22103031113036660018 ↗
40. 10.1615/CritRevTherDrugCarrierSyst.201400828510.1615/CritRevTherDrugCarrierSyst.2014008285 ↗
41. Kaur M · Drug Deliv · 2014
42. 10.1016/j.ijpharm.2011.11.04310.1016/j.ijpharm.2011.11.043 ↗
43. 10.1038/nbt117110.1038/nbt1171 ↗
44. 10.1016/S0140-6736(12)61766-810.1016/S0140-6736(12)61766-8 ↗
45. 10.1248/cpb.57.5510.1248/cpb.57.55 ↗
46. 10.1021/nl060162e10.1021/nl060162e ↗
47. 10.1016/B978-012373960-5.00335-X10.1016/B978-012373960-5.00335-X ↗
48. 10.1371/journal.pmed.003044210.1371/journal.pmed.0030442 ↗
49. 10.1161/CIRCULATIONAHA.107.71703310.1161/CIRCULATIONAHA.107.717033 ↗
50. Miyake F · Nihon Rinsho · 1998 · 56 · 737
51. 10.1016/S0142-9612(98)00004-010.1016/S0142-9612(98)00004-0 ↗
52. 10.1096/fj.04-2747rev10.1096/fj.04-2747rev ↗
53. 10.1126/science.111439710.1126/science.1114397 ↗
54. 10.3109/1073119940911792510.3109/10731199409117925 ↗
55. Parnami N · Artif Cells Nanomed Biotechnol · 2013
56. Patel SS. · Pharmainfonet · 2006 · 5 · 1
57. 10.1016/S0168-3659(03)00201-310.1016/S0168-3659(03)00201-3 ↗
58. Pi F · Yao Xue Xue Ba.o · 2010 · 45 · 1322
59. 10.1056/NEJM19980924339130110.1056/NEJM199809243391301 ↗
60. Sharma G · Int J Institut Pharm Life Sci · 2012 · 2 · 205
61. 10.1385/1-59259-813-7:00310.1385/1-59259-813-7:003 ↗
62. Singh H · Artif Cells Nanomed Biotechnol · 2014
63. Singh K · Am J Pharm Tech Res · 2012 · 2 · 113
64. Singh K · Int J Institut Pharm Life Sci · 2012 · 2 · 58
65. Singh O · J Pharm · 2014 · 1
66. 10.1016/S0168-3659(98)00016-910.1016/S0168-3659(98)00016-9 ↗
67. 10.1517/17425247.2013.77257810.1517/17425247.2013.772578 ↗
68. 10.1007/s10557-012-6437-610.1007/s10557-012-6437-6 ↗
69. 10.1016/j.addr.2012.09.03110.1016/j.addr.2012.09.031 ↗
70. 10.1155/2012/67329110.1155/2012/673291 ↗
71. 10.1182/blood.V99.3.91210.1182/blood.V99.3.912 ↗
72. 10.1016/j.biomaterials.2006.09.00310.1016/j.biomaterials.2006.09.003 ↗